Novel Therapies for Primary Central Nervous System Lymphomas

Area of Science:

• Neuro-oncology
• Hematology
• Immunology

Background:

• Primary Central Nervous System Lymphoma (PCNSL) is an aggressive malignancy with poor prognosis and limited treatment options for relapsed/refractory cases.
• Current 5-year survival rates for PCNSL remain low, underscoring the need for innovative therapeutic strategies.

Purpose of the Study:

• To review the evidence supporting novel therapeutic agents for PCNSL.
• To discuss ongoing clinical studies investigating new treatments for PCNSL.
• To explore the pathogenesis and oncogenic pathways driving PCNSL.

Main Methods:

• Literature review of recent studies on PCNSL pathogenesis and novel therapeutics.
• Analysis of clinical trial data for emerging treatments.
• Discussion of targeted therapies and immunotherapies.

Main Results:

• Key oncogenic drivers in PCNSL include NFkB pathway activation, cell cycle dysregulation, somatic hypermutation, and immune evasion.
• Investigational therapies include BTK inhibitors, mTOR/PI3K inhibitors, immunomodulatory agents (IMIDs), immune checkpoint inhibitors, and CD19-based CAR T-cells.
• The therapeutic landscape for PCNSL is rapidly evolving.

Conclusions:

• Novel targeted and immunotherapies show promise for PCNSL treatment.
• A multi-modality approach combining chemotherapy with novel agents is likely the future of PCNSL management.
• Further clinical studies are crucial to establish the efficacy of these emerging therapies.